REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
Monday, June 1, 2009 - 07:35
in Health & Medicine
Boston, MA ? June 1, 2009 ? REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD).
Read the whole article on Science Blog
More from Science Blog
Related
- REGiMMUNE presents enhanced efficacy data in preclinical transplantation modelsMon, 1 Jun 2009, 8:36:59 EDT
- Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host diseaseWed, 7 Oct 2009, 15:18:36 EDT
- UNC study hints at new approaches to prevent transplant rejectionWed, 11 Feb 2009, 11:17:14 EST
- Gene mismatch influences success of bone marrow transplantsSun, 22 Nov 2009, 14:50:48 EST
- Cancer drug shows promise against graft vs. host diseaseThu, 10 Jul 2008, 16:35:50 EDT